PEDDQLLQLNGBPM-UHFFFAOYSA-N
C30H32ClF3N8O3 — CID 155098492
Data last refreshed: (MolForge compound catalog, from PubChem)
About PEDDQLLQLNGBPM-UHFFFAOYSA-N
PEDDQLLQLNGBPM-UHFFFAOYSA-N (PubChem CID 155098492) has the molecular formula C30H32ClF3N8O3 and a molecular weight of 645.09 g/mol. Its IUPAC name is 5-[1-but-3-yn-2-yl-3-(trifluoromethyl)pyrazol-4-yl]-N-[3-chloro-4-[4-(piperidine-4-carbonyl)piperazine-1-carbonyl]phenyl]-1-methylimidazole-2-carboxamide.
Molecular Properties
| Compound Name | PEDDQLLQLNGBPM-UHFFFAOYSA-N |
|---|---|
| PubChem CID | 155098492 |
| Molecular Formula | C30H32ClF3N8O3 |
| Molecular Weight | 645.09 g/mol |
| Exact Mass | 644.22 |
| IUPAC Name | 5-[1-but-3-yn-2-yl-3-(trifluoromethyl)pyrazol-4-yl]-N-[3-chloro-4-[4-(piperidine-4-carbonyl)piperazine-1-carbonyl]phenyl]-1-methylimidazole-2-carboxamide |
| SMILES | C#CC(C)n1cc(-c2cnc(C(=O)Nc3ccc(C(=O)N4CCN(C(=O)C5CCNCC5)CC4)c(Cl)c3)n2C)c(C(F)(F)F)n1 |
| InChI | InChI=1S/C30H32ClF3N8O3/c1-4-18(2)42-17-22(25(38-42)30(32,33)34)24-16-36-26(39(24)3)27(43)37-20-5-6-21(23(31)15-20)29(45)41-13-11-40(12-14-41)28(44)19-7-9-35-10-8-19/h1,5-6,15-19,35H,7-14H2,2-3H3,(H,37,43) |
| InChIKey | PEDDQLLQLNGBPM-UHFFFAOYSA-N |
| XLogP | 3.69 |
| TPSA | 117.39 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 45 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 645.09 |
| LogP ≤ 5 | 3.69 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 8 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'triple_bond', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155098492 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.